Session » Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology
-
Abstract Number: 543
Disease Severity Among Bio-Naive RA Patients on Csdmards
-
Abstract Number: 544
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
-
Abstract Number: 545
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
-
Abstract Number: 546
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
-
Abstract Number: 547
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
-
Abstract Number: 548
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
-
Abstract Number: 549
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
-
Abstract Number: 550
Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
-
Abstract Number: 551
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
-
Abstract Number: 552
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
-
Abstract Number: 553
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
-
Abstract Number: 554
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
-
Abstract Number: 555
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
-
Abstract Number: 556
Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims
-
Abstract Number: 558
Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
-
Abstract Number: 559
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
-
Abstract Number: 560
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
-
Abstract Number: 562
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
-
Abstract Number: 564
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
-
Abstract Number: 565
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
-
Abstract Number: 566
Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
-
Abstract Number: 567
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
-
Abstract Number: 570
Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab
-
Abstract Number: 571
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
-
Abstract Number: 572
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
-
Abstract Number: 575
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
-
Abstract Number: 576
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
-
Abstract Number: 577
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
-
Abstract Number: 578
Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
-
Abstract Number: 579
Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
-
Abstract Number: 580
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
-
Abstract Number: 581
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
-
Abstract Number: 582
Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib
-
Abstract Number: 583
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
-
Abstract Number: 584
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
-
Abstract Number: 585
The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia
-
Abstract Number: 586
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort
-
Abstract Number: 588
Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
-
Abstract Number: 590
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
-
Abstract Number: 591
Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo
-
Abstract Number: 592
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
-
Abstract Number: 593
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
-
Abstract Number: 594
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
-
Abstract Number: 595
Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab
-
Abstract Number: 596
Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis
-
Abstract Number: 598
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
-
Abstract Number: 601
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
-
Abstract Number: 602
Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
-
Abstract Number: 603
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
-
Abstract Number: 606
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
-
Abstract Number: 607
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
-
Abstract Number: 608
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
-
Abstract Number: 609
Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
-
Abstract Number: 610
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
-
Abstract Number: 611
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
-
Abstract Number: 612
Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab
-
Abstract Number: 614
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
-
Abstract Number: 615
The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis
-
Abstract Number: 617
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
-
Abstract Number: 618
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
-
Abstract Number: 619
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
-
Abstract Number: 620
Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)
-
Abstract Number: 621
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
-
Abstract Number: 622
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
-
Abstract Number: 623
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
-
Abstract Number: 624
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
-
Abstract Number: 625
Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort
-
Abstract Number: 626
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis